BCL2L1 and head and neck squamous cell carcinoma: More recent reports have shown that inhibition of BCL-XL by an orally available ABT-737-derivative, ABT-263 (navitoclax), and MCL-1 by A-1210477 enhances apoptosis in HNSCC cells [46].